Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Addex raises 2.8M via ATM, extends cash runway to Q4 2027

Aug 26, 2026, 1:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Significant share dilution (~33%) from the ATM could depress near-term share price, even though liquidity improves; investors will weigh dilution against longer-term pipeline catalysts.

AI summary

What happened, with direct paths to the underlying reporting

Addex Therapeutics announced a USD 2.8 million gross raise through its ATM facility, issuing 437,869 ADSs representing 52,544,280 shares and extending its cash runway to Q4 2027. While liquidity improves, the roughly 33% increase in outstanding shares signals near-term dilution and could weigh on ADXN stock until pipeline milestones or more favorable financing terms emerge.

Addex raises USD 2.8M via ATM. ADS sale increases liquidity.
Cash runway extended to Q4 2027, reducing near-term financing risk.
Outstanding shares rise to 210,292,217; issued shares unchanged at 218,654,496.
ATM sale implies ~52.5M new shares, signaling dilution risk.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Addex raises 2.8M via ATM, extends cash runway to Q4 2027

Crude Oil Dips; Addex Therapeutics Shares Spike Higher